This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (44)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Recently, a membrane phospholipid hypothesis of schizophrenia has been proposed¹ that not only provides an underlying explanation for those aspects of schizophrenia traditionally explained by the dopamine hypothesis, but also can account for many other clinical features. These include the inverse relationship between schizophrenia and some inflammatory disorders; the high resistance to pain shown by some patients; the dramatic remission of symptoms that may occur with pyrexia; the increased risk associated with exposure to viral infections or maternal malnutrition during fetal development; and the difference in severity and prognosis in different countries.² Recent biochemical, cerebral magnetic resonance spectroscopy, and molecular genetics findings suggest that schizophrenia is associated with a cell membrane deficiency of arachidonic acid and docosahexaenoic acid (DHA), arising from excess activity of 1 of the phospholipase A₂ (PLA₂) group of enzymes.^3-7 Thus, there is mounting evidence for the membrane phospholipid hypothesis; however, an important issue for clinicians . . . [Full Text of this Article]

Report of a Case


Comment


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Current Clinical Applications of {Omega}-6 and {Omega}-3 Fatty Acids
Lee et al.
Nutr Clin Pract 2006;21:323-341.
ABSTRACT | FULL TEXT  

Omega-3 Fatty Acid for Schizophrenia
HORROBIN
Am. J. Psychiatry 2003;160:188-189.
FULL TEXT  

A Dose-Ranging Study of the Effects of Ethyl-Eicosapentaenoate in Patients With Ongoing Depression Despite Apparently Adequate Treatment With Standard Drugs
Peet and Horrobin
Arch Gen Psychiatry 2002;59:913-919.
ABSTRACT | FULL TEXT  

A Placebo-Controlled Trial of Omega-3 Fatty Acid (Ethyl Eicosapentaenoic Acid) Supplementation for Residual Symptoms and Cognitive Impairment in Schizophrenia
Fenton et al.
Am. J. Psychiatry 2001;158:2071-2074.
ABSTRACT | FULL TEXT  

Phospholipid Spectrum Disorder in Psychiatry: Edited by Malcolm Peet, Iain Glen and David F. Horrobin
Corrigan
Br. J. Psychiatry 2000;177 :191a-191a.
FULL TEXT